Unknown

Dataset Information

0

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.


ABSTRACT:

Background

This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression.

Methods

Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 only, MET overexpression. Tepotinib was administered once daily at 300 or 500 mg in Phase 1b ('3 + 3' design), and at the recommended Phase 2 dose (RP2D) in Phase 2. Primary endpoints were dose-liming toxicities (DLTs; Phase 1b) and 12-week investigator-assessed progression-free survival (PFS; Phase 2).

Results

In Phase 1b (n = 17), no DLTs occurred and the RP2D was confirmed as 500 mg. In Phase 2 (n = 49), the primary endpoint was met: 12-week PFS was 63.3% (90% CI: 50.5-74.7), which was significantly greater than the predefined null hypothesis of ≤15% (one-sided binomial exact test: P < 0.0001). Median time to progression was 4 months. In Phase 2, 28.6% of patients had treatment-related Grade ≥3 adverse events, including peripheral oedema and lipase increase (both 6.1%).

Conclusions

Tepotinib was generally well tolerated and the RP2D (500 mg) showed promising efficacy and, therefore, a positive benefit-risk balance in sorafenib pretreated aHCC with MET overexpression.

Trial registration

ClinicalTrials.gov: NCT02115373.

SUBMITTER: Decaens T 

PROVIDER: S-EPMC8292404 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8292411 | biostudies-literature
| S-EPMC5016063 | biostudies-literature
| S-EPMC4912375 | biostudies-literature
| S-EPMC8085979 | biostudies-literature
| S-EPMC7571806 | biostudies-literature
| S-EPMC5091321 | biostudies-literature
| S-EPMC5507650 | biostudies-literature
| S-EPMC3639524 | biostudies-literature
| S-EPMC4612326 | biostudies-literature
| S-EPMC8186405 | biostudies-literature